Corporate Presentation
Importance of nitric oxide, our pipeline, and our plans for market disruption.
-
A safety evaluation of intermittent high-dose inhaled nitric oxide in viral pneumonia due to COVID-19: a randomised clinical study
Talya Wolak, D. Dicker, Y. Shifer, A. Grossman, A. Rokach, M. Shitrit & A. Tal • July 2024 -
Effects of extended-release 7-nitroindazole gel formulation treatment on the behavior of Shank3 mouse model of autism. Nitric Oxide 140 (2023): 41-49.
Amal, H. et al. (2023) • September 2023 -
The NO Answer for Autism Spectrum Disorder. Advanced Science 2023,10, 2205783
M. K. Tripathi, S. K. Ojha, M. Kartawy, W. Hamoudi, A. Choudhary, S. Stern, A. Aran, H. Amal (2023) • June 2023 -
Poster Presentation: Phase 1 Study of Ultra-High Concentration Nitric Oxide (UNO) in Relapsed or Refractory, Unresectable, Primary, or Metastatic Cutaneous and Subcutaneous Malignancies
Frederick Dirbas, Amichay Meirovitz, Jedidiah M. Monson, David Greenberg, Amir Avniel • 11/3/2023 -
Neonatal Intensive Care | Interview: Benefits of LungFit PH System Compared to Cylinder-based Systems
• Summer 2023 -
RT For Decision Makers In Respiratory Care | Market Analysis: The Impact of Cylinder-free Systems on Inhaled Nitric Oxide Delivery
• JANUARY–FEBRUARY 2023 -
Short-Term Exposure of Cancer Cells to Ultra-High Concentrations of Nitric Oxide (UNO) Activates the mPD-1/mPD-L1 Axis and Immune Responses
Yana Epshtein, Matan Goldshtein, Selena Chaisson, Jedidiah M. Monson, Matt Johnson, Gavin Choy, Hila Confino • 04/19/2023 -
Intratumoral Administration of Ultra High-Concentration Nitric Oxide (UNO) is more Efficacious than anti-mPD-1 Therapy in 4T1 Tumor-Bearing Mice
Yana Epshtein, Matan Goldshtein, Selena Chaisson, Jedidiah M. Monson, Matt Johnson, Gavin Choy, Hila Confino • 04/19/2023 -
Respiratory Therapy: The Journal of Pulmonary Technique. Nitric Oxide from Room Air: The Development of the LungFit PH Technology.
Respiratory Therapy Vol. 18 No. 2 • Spring 2023 -
Intratumoral Administration of High-Concentration Nitric Oxide and Anti PD-1 Treatment Leads to Higher Tumor Regression Rates and Prolonged Survival in CT26 Tumor-Bearing Mice – Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Hila Confino, David Greenberg, Selena Chaisson, Jedd Monson, Steve Lisi, Amir Avniel, Ido Wolf, Yana Epshtein • 11/10/2022